With Strong Cash Flow, ResMed Stock Poised to Rise?

RMD: ResMed logo
RMD
ResMed

ResMed (RMD) could be a good pick for your portfolio, with its high cash yield, good fundamentals, and discounted valuation. Companies like this can use cash to fuel additional revenue growth, or simply pay their shareholders through dividends or buybacks. Either move makes them attractive to the market

RMD Has Good Fundamentals

  • Good Cash Yield: Not many stocks offer free cash flow yield of 5.9%, but ResMed stock does
  • Strong Margin: Last 12 month operating margin of 34.6%
  • Growth: Last 12 revenue growth of 10.3% – low growth, but this selection is all about high yield and margin
  • Valuation: RMD stock currently trading at 31% below 2Y high, 11% below 1M high, and at a PS lower than 3Y average.

Below is a quick comparison of RMD fundamentals with S&P medians.

  RMD S&P Median
Sector Health Care
Industry Health Care Equipment
Free Cash Flow Yield 5.9% 4.3%
   
Revenue Growth LTM 10.3% 7.4%
Revenue Growth 3YAVG 11.3% 5.7%
   
Operating Margin LTM 34.6% 18.4%
Operating Margin 3YAVG 31.6% 18.3%
   
PE Ratio 19.3 23.2

*LTM: Last Twelve Months

Relevant Articles
  1. Can PLTR Stock Live Up To Its Multiple?
  2. KO Stock: The Math Behind The Upside
  3. Under The Hood: The Real Range Wall Street Is Pricing For CSCO
  4. Cash Machine Trading Cheap – Waystar Stock Set to Run?
  5. Years of Rewards: $71 Bil From Home Depot Stock
  6. NVIDIA Stock Pays Out $96 Bil – Investors Take Note

While the fundamentals may look attractive, analyzing what has been driving the stock recently provides important context that puts financials in perspective.

And don’t forget, there is always a meaningful risk involved when exposing yourself to a single stock trade. One of the ways to understand that risk is to look at how RMD stock has behaved during past market crashes. In other words, how low can it really go, and are you willing to take that risk?

Trefis: RMD Stock Insights

Stocks Like RMD

Not ready to act on RMD? Consider these alternatives:

  1. Abbott Laboratories (ABT)
  2. Booking (BKNG)
  3. Marsh & McLennan (MRSH)

These stocks have high free cash flow yield, strong operating margin, are trading meaningfully below 2Y high, and have dipped notably during the last month.

A portfolio of stocks with the criteria above would have performed has follows since 12/31/2016:

  • Average 6-month and 12-month forward returns of 10.4% and 20.4% respectively
  • Win rate (percentage of picks returning positive) of about 74% for 12-month period
  • Strategy consistent across market cycles

Portfolios Over Single Stock Picks

The fundamental profile of RMD – robust cash yield paired with a multi-year valuation trough – represents a potential mean-reversion signal. However, while individual stock trades can look compelling, they trades carry idiosyncratic risks that even elite cash flows cannot fully hedge.

The Trefis High Quality Portfolio (HQ) follows objective and rule-based approach. By diversifying across 30 high-conviction names, the HQ strategy has outpaced the S&P 500, S&P Mid-cap, and Russell 2000.